What Percentage of Clinical Trial Patients Fail Screening? (And How to Reduce It)

Across all therapeutic areas, the average clinical trial screen failure rate is approximately 40–60%. In other words, for every 10 patients who begin the formal screening process, only 4 to 6 will ultimately qualify for enrollment. In highly restrictive protocols — particularly in oncology, rare disease, and CNS — screen failure rates of 70–80% or higher are not unusual.

What Is a Screen Failure?

A screen failure occurs when a patient who has consented to participate in screening assessments is found to be ineligible for enrollment based on the trial's inclusion/exclusion (I/E) criteria. The patient has already entered the formal screening process — meaning site resources have been consumed — but cannot be enrolled.

Screen failures are distinct from pre-screen failures (patients who don't meet obvious criteria before formal screening begins) and dropouts (patients who were enrolled but withdrew or were discontinued).

The Top Reasons Patients Fail Screening

1. Lab Values Out of Range (Most Common)

Specific biomarker thresholds (HbA1c, creatinine, liver enzymes, platelet counts) are frequent screen-failure triggers. These thresholds are often conservative, and many otherwise eligible patients fall just outside the window at the time of assessment.

2. Prohibited Concomitant Medications

Patients on excluded medications (common in CNS, oncology, and autoimmune trials) frequently can't participate without a washout period that many are unwilling or unable to complete.

3. Prior or Current Treatment History

Restrictions on prior lines of therapy, previous participation in similar trials, or prior exposure to the investigational drug are common exclusion criteria — and hard to capture accurately during pre-screening.

4. Disease Severity or Stage Mismatch

Protocols often require patients to be within a narrow window of disease severity. Patients presenting too early or too late in their disease course — even if they carry the correct diagnosis — will fail.

5. Comorbidities

Cardiovascular history, renal impairment, hepatic dysfunction, or other comorbidities are common exclusions, particularly in early-phase trials with tighter safety margins.

6. Investigator / Site Judgment

Protocol deviations, incomplete medical records, and investigator discretion (where permitted) account for a meaningful percentage of screen failures that aren't strictly criteria-driven.

The Real Cost of Screen Failure

Screen failures are not free. Each formal screen failure incurs:

• Site coordinator time for review, outreach, and documentation

• Diagnostic costs for labs, imaging, and assessments conducted before failure

• Recruitment funnel costs- every failed screener represents advertising spend that didn't convert

A study with a 70% screen failure rate and 300 patients to enroll must screen approximately 1,000 patients. If average screening costs per patient are $800 (lab work, coordinator time, administrative burden), that's $800,000 in screen failure costs alone, before counting the media and outreach spend required to generate 1,000 screened patients.

Reducing screen failure from 70% to 55% on the same study would require screening only ~667 patients, saving roughly $267,000 in direct screening costs, plus the downstream savings on referral generation.

How to Reduce Screen Failure Rates

Pre-Screen Before You Screen

The most effective intervention is a robust digital pre-screener that collects key eligibility data before a patient ever enters the formal screening process. Structured online questionnaires covering the most common failure criteria (age, diagnosis, medication history, recent lab values if available) filter out clearly ineligible patients before site resources are consumed.

A well-designed pre-screener can reduce formal screen failure rates by 15–25 percentage points by improving the quality of patients reaching the site.

Target Your Recruitment to High-Match Populations

Generic advertising that reaches a broad audience generates volume — but volume without qualification is expensive noise. Audience targeting based on diagnosis codes, condition-specific communities, and behavioral signals (e.g., people researching specific medications) improves pre-screen quality significantly.

Audit Your I/E Criteria Before the Trial Starts

Protocol complexity is the single largest driver of screen failure. Sponsors and medical teams should critically review each criterion before the protocol is finalized:

• Is this criterion scientifically necessary, or is it a legacy from prior protocols?

• Can any thresholds be relaxed without compromising safety or data integrity?

• Are any criteria so rare to fail that they add burden without meaningfully protecting the study?

FDA guidance has increasingly encouraged protocol feasibility review as a standard step in study design.

Use EHR and Real-World Data Matching

Identifying patients from existing healthcare data (EMR systems, registries, claims data) allows pre-qualification against structured clinical criteria before the patient is ever contacted. Patients identified this way have dramatically higher match rates because their eligibility is assessed against actual clinical records.

Educate Sites on Pre-Screening Best Practices

Sites vary widely in how rigorously they pre-screen before consenting patients to formal screening. Providing sites with clear pre-screening checklists, training on the most common failure reasons, and regular screen failure debriefs can meaningfully improve site-level performance.

Collect and Analyze Screen Failure Data in Real Time

Real-time dashboards that track failure reasons by site and by criterion allow rapid course correction. If a particular lab threshold is driving failures at three sites, that's actionable intelligence for protocol amendment or site retraining.

A Note on "Acceptable" Screen Failure Rates

There is no universal acceptable screen failure rate; it depends on the protocol, therapeutic area, and available patient population. What matters is whether your screen failure rate is:

1. Understood — you know why patients are failing and at what criteria

2. Benchmarked — you know how it compares to similar studies

3. Monitored — you're tracking it in real time

4. Actively managed — you have interventions in place to reduce it

A 60% screen failure rate that is well-understood and managed is far less damaging than a 40% rate that's drifting upward unnoticed.

Key Takeaways

• The average screen failure rate is 40–60% across all therapeutic areas; oncology and rare disease regularly exceed 70%.

• The most common failure reasons are lab values, prohibited medications, prior treatment history, and disease severity mismatch.

• Every screen failure has a real cost — in site resources, diagnostic spend, and recruitment funnel investment.

• Digital pre-screeners, targeted recruitment, and real-time data analysis are the highest-impact interventions.

• Protocol feasibility review before study launch is one of the most underutilized levers for reducing screen failure.

Average Screen Failure Rates by Therapeutic Area

Rates vary considerably by disease area, protocol complexity, and therapeutic area

Typical Screen Failure Rates by Therapeutic Area:

• Cardiovascular: 30–50%

• Diabetes / Metabolic: 25–45%

• Oncology: 60–80%

• Rare Disease: 50–75%

• CNS / Psychiatry: 50–70%

• Respiratory (e.g., COPD, Asthma): 35–55%

• Dermatology: 25–45%

• Infectious Disease: 30–55%

Figures drawn from Tufts CSDD research, ClinicalTrials.gov published data, and industry benchmarking. Rates represent formal screen failures after consent.